Calithera Biosciences Company Profile (NASDAQ:CALA)

About Calithera Biosciences

Calithera Biosciences logoCalithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CALA
  • CUSIP:
Key Metrics:
  • Previous Close: $8.95
  • 50 Day Moving Average: $6.03
  • 200 Day Moving Average: $3.84
  • 52-Week Range: $20,737,000.00 - $2.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.82
  • P/E Growth: -0.06
  • Market Cap: $200.74B
  • Outstanding Shares: 20,737,000
  • Beta: 3.18
Profitability:
  • Return on Equity: -58.24%
  • Return on Assets: -54.26%
Debt:
  • Current Ratio: 12.21%
  • Quick Ratio: 12.21%
Additional Links:
Companies Related to Calithera Biosciences:

Analyst Ratings

Consensus Ratings for Calithera Biosciences (NASDAQ:CALA) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $9.75 (5.98% upside)

Analysts' Ratings History for Calithera Biosciences (NASDAQ:CALA)
Show:
DateFirmActionRatingPrice TargetDetails
2/2/2017HC WainwrightSet Price TargetBuy$10.00View Rating Details
1/30/2017JMP SecuritiesReiterated RatingOutperform$12.00View Rating Details
1/24/2017Citigroup Inc.UpgradeSell -> Neutral$5.00View Rating Details
5/12/2016Wells Fargo & CompanyReiterated RatingBuyView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$20.00 -> $12.00View Rating Details
11/10/2015Leerink SwannLower Price TargetOutperform$19.00 -> $13.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Calithera Biosciences (NASDAQ:CALA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
5/10/2016Q1($0.47)($0.52)ViewListenView Earnings Details
3/15/2016Q415($0.56)($0.44)ViewListenView Earnings Details
11/9/2015Q3($0.52)($0.49)ViewListenView Earnings Details
8/10/2015Q215($0.45)($0.44)ViewListenView Earnings Details
11/17/2014($0.28)($16.85)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Calithera Biosciences (NASDAQ:CALA)
Current Year EPS Consensus Estimate: $-1.98 EPS
Next Year EPS Consensus Estimate: $-1.58 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.52)($0.52)($0.52)
Q3 20161($0.56)($0.56)($0.56)
Q4 20161($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Calithera Biosciences (NASDAQ:CALA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Calithera Biosciences (NASDAQ:CALA)
Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 37.93%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2016Adage Capital Partners Gp, L.LMajor ShareholderBuy500,000$3.15$1,575,000.00View SEC Filing  
11/16/2015Curtis HechtVPSell970$6.58$6,382.60View SEC Filing  
9/23/2015Adage Capital Partners Gp LlcMajor ShareholderBuy106,968$6.03$645,017.04View SEC Filing  
9/4/2015Adage Capital Partners Gp LlcMajor ShareholderBuy90,300$5.93$535,479.00View SEC Filing  
8/28/2015Adage Capital Partners Gp LlcMajor ShareholderBuy172,126$5.27$907,104.02View SEC Filing  
10/15/2014Adage Capital Partners Gp LlcMajor ShareholderBuy181,700$6.96$1,264,632.00View SEC Filing  
10/7/2014Jean GeorgeDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
10/7/2014Morgenthaler Venture PartnersMajor ShareholderBuy350,000$10.00$3,500,000.00View SEC Filing  
10/1/2014Adage Capital Partners Gp LlcMajor ShareholderBuy800,000$10.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Calithera Biosciences (NASDAQ:CALA)
DateHeadline
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) Price Target Set At $10 - Transcript Daily (NASDAQ:CALA)
transcriptdaily.com - February 19 at 3:53 PM
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) Bearish Target At $10 - Stock Observer (NASDAQ:CALA)
www.thestockobserver.com - February 18 at 3:59 PM
News IconThe Technicals For Calithera Biosciences, Inc. (CALA) Have Been Dissected (Brutally) - NY Stock News (NASDAQ:CALA)
nystocknews.com - February 18 at 3:59 PM
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) Price Target At $10 - Transcript Daily (NASDAQ:CALA)
transcriptdaily.com - February 15 at 2:52 AM
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) Long-Term Growth Estimate At $75 - Transcript Daily (NASDAQ:CALA)
transcriptdaily.com - February 12 at 4:07 PM
News IconPrice Target Of Calithera Biosciences, Inc. (NASDAQ:CALA)At $10 - Transcript Daily (NASDAQ:CALA)
transcriptdaily.com - February 10 at 3:44 PM
News IconConsensus Price Of Calithera Biosciences, Inc. (NASDAQ:CALA ... - Transcript Daily (NASDAQ:CALA)
transcriptdaily.com - February 9 at 9:26 PM
News IconOverbuying Stock in Focus: Calithera Biosciences Inc (NASDAQ:CALA) - Post Registrar (NASDAQ:CALA)
postregistrar.com - February 9 at 9:26 PM
finance.yahoo.com logoCalithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February (NASDAQ:CALA)
finance.yahoo.com - February 9 at 4:23 PM
News IconOverbuying Stock in Limelight: Calithera Biosciences Inc (NASDAQ ... - Post Registrar (NASDAQ:CALA)
postregistrar.com - February 8 at 3:11 AM
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) Mean Price Target At $10 - Transcript Daily (NASDAQ:CALA)
transcriptdaily.com - February 6 at 4:10 PM
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) shows Price to Sale ratio of 0 - The Newburgh Press (NASDAQ:CALA)
newburghpress.com - February 4 at 2:26 AM
News IconBroker Outlook For The Week Ahead Calithera Biosciences, Inc. (NASDAQ:CALA) (NASDAQ:CALA)
thecelebritytruth.com - February 1 at 8:18 PM
News IconIncrease in Volatility Draws Attention to Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) - Wall Street Beacon (NASDAQ:CALA)
wsbeacon.com - February 1 at 3:17 PM
marketexclusive.com logoCalithera Biosciences Inc (NASDAQ:CALA): What You Need To Know (NASDAQ:CALA)
marketexclusive.com - January 31 at 4:32 PM
rttnews.com logoCalithera Biosciences Inc. (CALA) Surged To A 10-Month High On Incyte Deal (NASDAQ:CALA)
www.rttnews.com - January 31 at 4:32 PM
investopedia.com logoIncyte Pays $53M for Calithera Cancer Drug (INCY, CALA) (NASDAQ:CALA)
www.investopedia.com - January 31 at 4:32 PM
finance.yahoo.com logoCalithera Biosciences (CALA) In Focus: Stock Jumps 46.7% (NASDAQ:CALA)
finance.yahoo.com - January 31 at 4:32 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Calithera Biosciences (CALA) Stock? (NASDAQ:CALA)
finance.yahoo.com - January 31 at 4:31 PM
finance.yahoo.com logoBiotech Acquisitions on the Rise in 2017: Latest Reports on Calithera Biosciences and Evoke Pharma (NASDAQ:CALA)
finance.yahoo.com - January 31 at 4:31 PM
finance.yahoo.com logoIncyte and Calithera Enter into Deal for Oncology Candidate (NASDAQ:CALA)
finance.yahoo.com - January 31 at 4:31 PM
investopedia.com logoIncyte Pays $53M for Calithera’s Oncology Drug (NASDAQ:CALA)
www.investopedia.com - January 31 at 4:31 PM
insidermonkey.com logoCalithera Biosciences Inc (CALA): What You Need To Know (NASDAQ:CALA)
www.insidermonkey.com - January 31 at 4:31 PM
News IconHigh Volatility Moving the Needle For Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) - Wall Street Beacon (NASDAQ:CALA)
wsbeacon.com - January 31 at 2:14 AM
marketexclusive.com logoHome SEC Filings Calithera Biosciences, Inc. (NASDAQ:CALA) Files An 8-K Entry into a Material Definitive... - Market Exclusive (NASDAQ:CALA)
marketexclusive.com - January 31 at 2:14 AM
streetinsider.com logoIncyte (INCY) and Calithera Biosciences (CALA) Enter Pact to Develop and Commercialize CB-1158 - StreetInsider.com (NASDAQ:CALA)
www.streetinsider.com - January 31 at 2:14 AM
News IconIncyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize ... (NASDAQ:CALA)
www.biomedreports.com - January 30 at 4:09 PM
proactiveinvestors.co.uk logoCalithera soars as Incyte signs collaboration deal (NASDAQ:CALA)
www.proactiveinvestors.co.uk - January 30 at 4:09 PM
finance.yahoo.com logoIncyte and Calithera Biosciences Announce Global Collaboration to Develop and ... (NASDAQ:CALA)
finance.yahoo.com - January 30 at 4:09 PM
streetinsider.com logoIncyte (INCY), Calithera Biosciences (CALA) Enter Collaboration to Develop and Commercialize CB-1158 (NASDAQ:CALA)
www.streetinsider.com - January 30 at 4:09 PM
rttnews.com logoCalithera Biosciences Inc. (CALA) Is Up Sharply On Incyte Collaboration (NASDAQ:CALA)
www.rttnews.com - January 30 at 4:09 PM
finance.yahoo.com logo6:46 am Calithera Biosciences & Incyte (INCY (NASDAQ:CALA)
finance.yahoo.com - January 30 at 4:08 PM
finance.yahoo.com logoWhy This Collaboration Is So Important for Calithera (NASDAQ:CALA)
finance.yahoo.com - January 30 at 4:08 PM
bizjournals.com logo$53M deal: Incyte acquires rights to experimental cancer therapy (NASDAQ:CALA)
www.bizjournals.com - January 30 at 4:08 PM
News IconADX Watch on Shares of Calithera Biosciences Inc. (CALA ... - Sherwood Daily (NASDAQ:CALA)
sherwooddaily.com - January 27 at 10:22 PM
News IconEPS Forecast Of Calithera Biosciences, Inc. (NASDAQ:CALA) Set At $-0.36 - Transcript Daily (NASDAQ:CALA)
transcriptdaily.com - January 26 at 4:56 PM
News IconStock Seesawing as Volatility Sweeps in on Calithera Biosciences, Inc. (NASDAQ:CALA) - Wall Street Beacon (NASDAQ:CALA)
wsbeacon.com - January 26 at 4:56 PM
News IconStock Cutting The Mustard Mid-Session: Calithera Biosciences, Inc. (NASDAQ:CALA) - Aiken Advocate (NASDAQ:CALA)
aikenadvocate.com - January 25 at 5:12 PM
News IconStock to Watch: Calithera Biosciences, Inc. (NASDAQ:CALA) - The Tribune (NASDAQ:CALA)
lakecitytribune.com - January 24 at 9:41 PM
News IconInvestor Notebook: Focusing in on Shares of Calithera Biosciences Inc. (CALA) - Sherwood Daily (NASDAQ:CALA)
sherwooddaily.com - January 24 at 9:41 PM
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) Price Target At $9 - Transcript Daily (NASDAQ:CALA)
transcriptdaily.com - January 24 at 9:41 PM
247wallst.com logo4 Speculative Biotech and Biohealth Analyst Upgrades (NASDAQ:CALA)
247wallst.com - January 24 at 4:39 PM
us.rd.yahoo.com logoCalithera Biosciences upgraded by Citigroup (NASDAQ:CALA)
us.rd.yahoo.com - January 24 at 4:39 PM
News IconChart Trading: Viewing CCI and ADX Levels for Calithera Biosciences Inc. (CALA) - Sherwood Daily (NASDAQ:CALA)
sherwooddaily.com - January 23 at 2:08 AM
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) Price Target Set At $9 - Transcript Daily (NASDAQ:CALA)
transcriptdaily.com - January 21 at 9:05 PM
News IconWhat are the Levels Indicating for This Stock: Calithera Biosciences Inc. (CALA) - Sherwood Daily (NASDAQ:CALA)
sherwooddaily.com - January 19 at 10:19 PM
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) Daily Sentiment Score At 0.449 - Stock Observer (NASDAQ:CALA)
www.thestockobserver.com - January 18 at 8:37 PM
News IconShort Interest Filing: Calithera Biosciences Incorporated (NASDAQ ... - Baxley Report (NASDAQ:CALA)
baxleyreport.com - January 18 at 3:35 PM
News IconStock Mounting Higher Mid-Session: Calithera Biosciences, Inc. (NASDAQ:CALA) - Wall Street Beacon (NASDAQ:CALA)
wsbeacon.com - January 13 at 4:51 PM
News IconCalithera Biosciences, Inc. (NASDAQ:CALA) Bearish Target At $9 - Stock Observer (NASDAQ:CALA)
www.thestockobserver.com - January 13 at 4:51 PM

Social

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Where is Calithera Biosciences' stock going? Where will Calithera Biosciences' stock price be in 2017?

5 brokerages have issued 12-month target prices for Calithera Biosciences' shares. Their predictions range from $5.00 to $12.00. On average, they anticipate Calithera Biosciences' stock price to reach $9.75 in the next twelve months.

When will Calithera Biosciences announce their earnings?

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Calithera Biosciences stock?

Calithera Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (1.86%) and Oxford Asset Management (0.24%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp Llc, Adage Capital Partners Gp, LL and Curtis Hecht.

Who bought Calithera Biosciences stock? Who is buying Calithera Biosciences stock?

Calithera Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management and FMR LLC. Company insiders that have bought Calithera Biosciences stock in the last two years include Adage Capital Partners Gp Llc and Adage Capital Partners Gp, LL.

How do I buy Calithera Biosciences stock?

Shares of Calithera Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Calithera Biosciences stock cost?

One share of Calithera Biosciences stock can currently be purchased for approximately $9.20.

Calithera Biosciences (NASDAQ:CALA) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Earnings History Chart

Earnings by Quarter for Calithera Biosciences (NASDAQ:CALA)

Dividend History Chart

Dividend Payments by Quarter for Calithera Biosciences (NASDAQ:CALA)

Last Updated on 2/19/2017 by MarketBeat.com Staff